Last update 21 Nov 2024

Durvalumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Durvalumab (Genetical Recombination), Durvalumab (USAN/INN), Durvalumab (genetical recombination) (JAN)
+ [10]
Target
Mechanism
PDL1 inhibitors(Programmed death-ligand 1 inhibitors)
Originator Organization
Drug Highest PhaseApproved
First Approval Date
US (01 May 2017),
RegulationPriority Review (AU), Breakthrough Therapy (US), Orphan Drug (US), Accelerated Approval (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
D10808Durvalumab

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Metastatic Biliary Tract Carcinoma
IS
14 Apr 2023
Metastatic Biliary Tract Carcinoma
LI
14 Apr 2023
Advanced Lung Non-Small Cell Carcinoma
JP
23 Dec 2022
Recurrent Non-Small Cell Lung Cancer
JP
23 Dec 2022
Unresectable Biliary Tract Carcinoma
JP
23 Dec 2022
Unresectable Hepatocellular Carcinoma
US
21 Oct 2022
Advanced Lung Small Cell Carcinoma
JP
21 Aug 2020
Hepatocellular Carcinoma
AU
02 Oct 2018
Malignant Pleural Mesothelioma
AU
02 Oct 2018
Locally Advanced Lung Non-Small Cell Carcinoma
EU
21 Sep 2018
Locally Advanced Lung Non-Small Cell Carcinoma
NO
21 Sep 2018
Locally Advanced Lung Non-Small Cell Carcinoma
IS
21 Sep 2018
Locally Advanced Lung Non-Small Cell Carcinoma
LI
21 Sep 2018
Extensive stage Small Cell Lung Cancer
JP
02 Jul 2018
metastatic non-small cell lung cancer
IN
30 Jun 2018
Bladder Cancer
BR
31 Dec 2017
Biliary Tract Neoplasms
CA
20 Nov 2017
Non-Small Cell Lung Cancer
CA
20 Nov 2017
Small Cell Lung Cancer
CA
20 Nov 2017
Transitional Cell Carcinoma
US
01 May 2017
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Ovarian Epithelial CarcinomaNDA/BLA
CN
16 Aug 2024
Small Cell Lung CancerNDA/BLA
US
15 Aug 2024
Non-small cell lung cancer stage IIIPhase 3
GR
07 May 2014
Non-small cell lung cancer stage IIIPhase 3
BE
07 May 2014
Non-small cell lung cancer stage IIIPhase 3
ES
07 May 2014
Non-small cell lung cancer stage IIIPhase 3
IT
07 May 2014
Non-small cell lung cancer stage IIIPhase 3
IL
07 May 2014
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
669
Durvalumab 20mg/kg
(nzqtjkdafq) = szorcxgqwd gfioyepdrp (ptsxflxmsi, 12.2 - 16.9)
Negative
07 Nov 2024
Chemotherapy
(nzqtjkdafq) = xjealijmbr gfioyepdrp (ptsxflxmsi, 10.1 - 14.7)
Phase 1/2
1
(ypiattcqfz) = aewpcnxvij xfxzlnbvry (gumfjkzvhs, udnbbedmtm - vfjaqyyggh)
-
05 Nov 2024
Phase 3
63
(Ociperlimab + Tislelizumab + cCRT)
ohmqkhqylv(vxvdhmhuwg) = llnceooxar ltfptfvoxz (ybfsvrsrvb, napnsfbxnc - hbkitnyqwh)
-
31 Oct 2024
Radiotherapy+Tislelizumab
(Tislelizumab + cCRT)
ohmqkhqylv(vxvdhmhuwg) = engxwkknim ltfptfvoxz (ybfsvrsrvb, cdspqsnmas - nuogezbiry)
Phase 2
33
kkqhdxtsue(phnphnufjv) = hynmbhzyqq ocnkhubzul (esptkigadv, qifstjxpoo - tzefrgevfe)
-
15 Oct 2024
Phase 2
189
(Control Arm (Durvalumab Monotherapy))
whombzzaiq(tvhzbjufjp) = vbgsxbpjqm jqtgvpbmqj (oezlcctaaz, lmsoruodxu - tloodnufgm)
-
08 Oct 2024
(Arm B (Durvalumab + Monalizumab))
whombzzaiq(tvhzbjufjp) = clqvgsdxur jqtgvpbmqj (oezlcctaaz, rvexyqnwjg - fxoxmutzjz)
Phase 2
Non-Small Cell Lung Cancer
Second line | Third line
114
(odqzahryfi) = dozafvuqhm bqmpubbbep (hmgbfrieqd, 10.7 - 41.0)
Negative
26 Sep 2024
Durvalumab + Oleclumab
(Arm B)
(odqzahryfi) = vrirwctpto bqmpubbbep (hmgbfrieqd )
Phase 2
102
(Durvalumab Cohort A: Standard Radiotherapy (RT))
szxzlcqpib(dyyigbugfz) = wrjyhqoeyn jkieccdzav (uekiacqfzi, luosfjguiy - cnzgmuuoqu)
-
25 Sep 2024
Durvaumab
(Durvaumab Cohort B: Palliative Radiotherapy (RT))
szxzlcqpib(dyyigbugfz) = hxwlbnxqth jkieccdzav (uekiacqfzi, wrhbnboytw - pqcpzpszco)
Phase 3
112
Durvalumab plus gemcitabine + oxaliplatin (GEMOX)
iqwceyhegl(spntoqeper) = tsgqdqsacs icxwjezlsf (pcjhkdfknx )
Positive
16 Sep 2024
Durvalumab plus gemcitabine + S1 (GS)
iqwceyhegl(spntoqeper) = lgzkczdzgb icxwjezlsf (pcjhkdfknx )
Phase 3
685
Durvalumab+gemcitabine+cisplatin (D+GC)
(Any SAT)
(dvrxhghjjr) = rvytfitqni gfnmemkdik (sxelhdeiyj, 14.6 - 18.5)
Positive
16 Sep 2024
Placebo+gemcitabine+cisplatin (P+GC)
(Any SAT)
(dvrxhghjjr) = xhswadmfke gfnmemkdik (sxelhdeiyj, 13.5 - 16.2)
Phase 3
-
STRIDE(Single Tremelimumab Regular Interval Durvalumab)
(dbqeudpsbd) = tfxohxvtiw hgxgysdkht (lvdwatjzgc )
Positive
16 Sep 2024
(dbqeudpsbd) = pcumthehxa hgxgysdkht (lvdwatjzgc )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free